By Notice dated August 15, 2006, and published in the Federal Register on August 22, 2006, (71 FR 48947), Noramco Inc., Division of Ortho-McNeil, Inc., 500 Old Swedes Landing Road, Wilmington, Delaware 19801, made application by renewal, and by separate correspondence dated June 2, Start Printed Page 280762006, and July 25, 2006, to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances listed in schedule I and II:
The company plans to bulk manufacture the above listed controlled substances for sale and distribution to manufacturers for product development and formulation.
By letter dated January 4, 2007, Noramco has withdrawn their request for Amphetamine (1100) and Methylphenidate (1724).
No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of Noramco Inc. to manufacture the listed basic classes of controlled substances is consistent with the public interest at this time. DEA has investigated Noramco Inc. to ensure that the company's registration is consistent with the public interest. The investigation has included inspection and testing of the company's physical security systems, verification of the company's compliance with State and local laws, and a review of the company's background and history. Therefore, pursuant to 21 U.S.C. 823, and in accordance with 21 CFR 1301.33(a), the above named company is granted registration as a bulk manufacturer of the basic classes of controlled substances listed.Start Signature
Dated: May 8, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.
[FR Doc. E7-9631 Filed 5-17-07; 8:45 am]
BILLING CODE 4410-09-P